NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CERO

CERo Therapeutics Holdings Inc

Jun 30 • 04:00PM ET

9.63

Dollar change +0.08
Percentage change 0.84	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX INO VXRT PGEN CTMX ADVM TFFP APVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-498.80	Insider Own	29.58%	Shs Outstand	0.52M	Perf Week	18.01%
Market Cap	4.97M	Forward P/E	-	EPS next Y	-56.90	Insider Trans	0.00%	Shs Float	0.36M	Perf Month	-6.87%
Enterprise Value	3.57M	PEG	-	EPS next Q	-70.20	Inst Own	6.79%	Short Float	8.90%	Perf Quarter	-35.89%
Income	-11.46M	P/S	-	EPS this Y	51.33%	Inst Trans	-	Short Ratio	0.03	Perf Half Y	-92.27%
Sales	0.00M	P/B	-	EPS next Y	68.65%	ROA	-114.10%	Short Interest	0.03M	Perf YTD	-91.97%
Book/sh	-10.36	P/C	0.96	EPS next 5Y	47.98%	ROE	-4090.08%	52W High	895.40 -98.92%	Perf Year	-98.32%
Cash/sh	10.07	P/FCF	-	EPS past 3/5Y	-35.78% -	ROIC	-5432.19%	52W Low	6.71 43.52%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.15% 23.93%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.28%	Oper. Margin	-	ATR (14)	2.55	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.73	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.92	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.73	EPS Q/Q	89.82%	SMA20	1.09%	Beta	0.49	Target Price	45.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-20.11%	Rel Volume	0.12	Prev Close	9.55
Employees	-	LT Debt/Eq	-	Earnings	May 28	SMA200	-90.69%	Avg Volume	1.14M	Price	9.63
IPO	Nov 30, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-57.88% -	Trades		Volume	135,272	Change	0.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-25	Upgrade	D. Boral Capital	Hold → Buy	$30

Jun-23-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 (GlobeNewswire) -23.60%
Jun-17-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire) +188.73%
Jun-12-25 09:15AM	Cero Therapeutics announces 1-for-20 reverse stock split (TipRanks) +6.64%
Jun-11-25 09:10AM	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire)
Jun-06-25 08:15AM	CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing (GlobeNewswire) +6.19%
09:20AM	Loading…
Jun-03-25 09:20AM	Cero announces two granted U.S. patents, European patent application allowance (TipRanks)
Jun-02-25 09:05AM	CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236 (GlobeNewswire)
May-30-25 08:15AM	CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations (GlobeNewswire) -13.85%
May-08-25 08:15AM	CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) (GlobeNewswire)
Apr-30-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) -6.11%
Apr-25-25 08:15AM	CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (GlobeNewswire) -19.81%
Apr-24-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +38.85%
Apr-22-25 08:15AM	CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing (GlobeNewswire) +18.70%
Apr-10-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 (GlobeNewswire) -7.89%
Apr-09-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +18.58%
08:15AM	Loading…
Mar-31-25 08:15AM	CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors (GlobeNewswire)
Mar-27-25 08:15AM	CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing (GlobeNewswire) -9.51%
Mar-19-25 08:15AM	CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services (GlobeNewswire)
Mar-13-25 08:15AM	CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting (GlobeNewswire) -29.40%
Mar-06-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays (GlobeNewswire)
Mar-05-25 08:15AM	CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14 (GlobeNewswire)
Feb-06-25 08:15AM	CERo Therapeutics Holdings, Inc. Highlights Progress (GlobeNewswire)
Feb-05-25 08:00PM	CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-07-25 08:13AM	Cero Therapeutics to effect 1-for-100 reverse stock split (TipRanks) +23.64%
Jan-06-25 08:00AM	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire) -27.32%
Dec-06-24 09:00AM	CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO (GlobeNewswire) -39.95%
Nov-15-24 08:45AM	CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia (GlobeNewswire) +52.40%
Nov-11-24 08:15AM	CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity (GlobeNewswire) +180.00%
Oct-21-24 09:00AM	CERo Therapeutics, Inc. Provides Corporate Update (GlobeNewswire)
Oct-02-24 09:15AM	CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer (GlobeNewswire) -14.23%
09:17AM	Loading…
Sep-25-24 09:17AM	CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 (GlobeNewswire) +6.72%
Jul-08-24 08:00AM	CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 (GlobeNewswire) -18.46%
Jun-13-24 08:15AM	CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 (GlobeNewswire) -48.86%
Jun-06-24 10:15AM	Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy (ACCESSWIRE) -16.47%
08:00AM	CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 (GlobeNewswire)
May-15-24 08:00AM	CERo Therapeutics, Inc. Provides Corporate Update for Shareholders (GlobeNewswire)
Apr-30-24 09:00AM	CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes (GlobeNewswire)
Mar-07-24 07:00AM	CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients (Business Wire) +20.78%
Feb-14-24 04:48PM	Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination (Business Wire) -16.24%
Jun-05-23 08:00AM	CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics (Business Wire)

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ATWOOD BRIAN G	Director	Mar 31 '25	Option Exercise	0.00	294,460	29	490,534	Apr 04 07:12 PM
YK Bioventures Opportunities G	10% Owner	Dec 13 '24	Sale	0.06	2,998,908	179,934	13,005,169	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 12 '24	Sale	0.07	1,614,541	113,018	16,004,077	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 11 '24	Sale	0.08	1,343,801	107,504	17,618,618	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 06 '24	Sale	0.12	1,236,874	148,425	21,383,909	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 10 '24	Sale	0.09	1,570,947	141,385	18,962,419	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 09 '24	Sale	0.11	850,543	93,560	20,533,366	Dec 10 08:44 PM
SLOAN STUART M	10% Owner	Sep 25 '24	Sale	0.10	532,486	55,538	21,067,956	Nov 20 04:04 PM
YK Bioventures Opportunities G	10% Owner	Oct 10 '24	Sale	0.10	3,250,000	325,000	22,620,783	Nov 14 08:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CERO

CERo Therapeutics Holdings Inc

Upgrade your FINVIZ experience